Marshall, Gerstein & Borun Named Patent Strategy and Management Team of the Year by LMG Life Sciences

September 30, 2013

Marshall, Gerstein & Borun LLP was recognized as Patent Strategy and Management: Team of the Year by LMG Life Sciences during the LMG Life Sciences Awards ceremony held on September 25, 2013 at the Essex House in New York City. The Firm was also shortlisted for Patent Prosecution: Firm of the Year, partner Li-Hsien (Lily) Rin-Laures, M.D. was a finalist for Patent Prosecution: Attorney of the Year (Pharmaceuticals), and partner David A. Gass was a finalist for Patent Prosecution: Attorney of the Year (Medical Devices). The full list of awardees is available here.

LMG Life Sciences is the publisher of an annual guide aimed at providing attorneys and law firms with information on the legal market and the U.S. life sciences industry. In the 2013 LMG Life Sciences guide, Marshall, Gerstein & Borun is highly recommended for patent prosecution and for patent strategy and management. Additionally, the following individuals were recognized as Life Sciences Stars for their outstanding patent work in life sciences:

Marshall, Gerstein & Borun’s large Biotechnology Group includes lawyers and patent agents with broad experience in a variety of biotechnology disciplines, including: DNA, RNA, vaccine, protein, and antibody therapeutics and diagnostics; cell-based and viral therapeutics; drug and gene therapy delivery vehicles; plant biotechnology; industrial technology and research platforms; nanotechnology and interdisciplinary inventions. The Firm’s professionals are skilled at providing patent counseling relating to the interface between patents, clinical product development, FDA regulations and regulatory exclusivity. The Firm is experienced in traditional, chemical-based pharmaceuticals, formulations, and delivery technologies. The Firm has procured, enforced and/or defended patents for biotech companies relating to a number of billion-dollar biologic or pharmaceutical products and handled key patents for clients covering more than a dozen different commercially marketed products and numerous clinical trial candidates.